CLINICAL_TRIALS
trial_result
· 2015-03-04
Clinical Trial Update: Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma [Phase 2]
Summary
Phase 2 trial of pomalidomide in gene expression profiling-defined high-risk multiple myeloma has completed; results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-04